• Journal of Periodontal and Implant Science
• /
• 제29권3호
• /
• pp.507-519
• /
• 1999

The ultimate objective of periodontal treatment is to stop disease progression and to regenerate destroyed periodontal tissues and thereby regain normal function. Growth factors are naturally found polypetides which stimulate many cellular activities pertaining to wound healing by acting as signal molecule in controlling cell movement, proliferation, and matrix production. Platelet derived growth factor (PDGF) is 28,000-35,000 Da molecular weight dimeric protein with 2 long positively charged polypeptide chains connected by sulfide bonds. The purpose of this study is to evaluate histologically the initial guided tissue regeneration in a periodontal defect f a beagle dog treated with a biodegradable membrane formed with polylactic acid (poly-L-lactic acid) and polyglycolic acid loaded with 200ng/$cm^2$ platelet derived growth factor. 2 beagle dogs were used in he experiment. $5mm{\times}6mm$ alveolar bone defect was formed in upper and lower canines and third premolars and a reference notch was placed. PDGF-BB non-containing membrane was used as control. Each defect was randomly assigned to the test roup or the control group. The dogs were sacrificed 3 weeks after membrane placement. Toluidine blue and multiple staining was done for histological analysis. In the 3 week specimen in the control group, no new one formation could be seen. Small amount f bone resorption below the notch could be seen. In the notch, loose connective tissue with infiltration of inflammatory cells could be seen. Also thin discontinuous new cementum could be seen and the membrane still retained its structure. Where PDGF-BB containing membrane was used, new bone formation could be seen in the notch at weeks and also continuous thin cementum could be seen. PDL cells were observed between new bone and new cementum and some were attached to bone and cementum. These results suggest that new bone and cementum formation seen when PDGF-BB loaded membrane was used was due to inhibition of downgrowth of epithelial cells and also due to continuous release of the growth factor. Further study on the resorption characteristics of the membrane nd the release characteristics of the PDGF-BB is necessary. Also, development of a membrane easier to use clinically is necessary.

• Journal of Chest Surgery
• /
• 제51권5호
• /
• pp.312-321
• /
• 2018

Background: Treatment strategies for octogenarians with lung cancer remain controversial. The purpose of this study was to compare surgical outcomes and survival between octogenarians and younger patients with stage IA and IB lung cancer. Methods: We reviewed the medical records of 34 consecutive octogenarians and 457 younger patients (<70 years) with stage I lung cancer who underwent surgical resection from January 2007 to December 2015. We analyzed the survival and surgical outcomes of the 2 groups according to the lung cancer stage (IA and IB). Results: The only significant differences in the clinicopathological features between the groups were the higher proportion of sublobar resection (56.3% vs. 18.9%) and the smaller number of dissected lymph nodes (LNs) in octogenarians. There was no significant difference in hospital stay (11 days vs. 9 days), pneumonia (5.8% vs 1.9%), or operative mortality (0% vs 0.6%) between the 2 groups. Among patients with stage IA lung cancer, 5-year recurrence-free survival was not significantly different between the octogenarians (n=16) and younger patients (n=318) (86.2% vs. 89.1%, p=0.548). However, 5-year overall survival was significantly lower in octogenarians than in younger patients (79.4% vs. 93.4%, p=0.009). Among patients with stage IB lung cancer, there was no significant difference in 5-year recurrence-free survival (62.1% vs. 73.5%, p=0.55) or overall survival (77.0% vs 85.0%, p=0.75) between octogenarians (n=18) and younger patients (n=139). In multivariable analysis, male sex, the number of dissected LNs, and tumor size were factors related to survival (hazard ratio [HR], 5.795; p=0.017; HR, 0.346, p=0.025; and HR, 1.699; p=0.035, respectively). Conclusion: Surgical outcomes and survival after pulmonary resection for stage I lung cancer were comparable in octogenarians and younger patients. Continued careful selection of octogenarians for pulmonary resection is important to achieve good results.

• Maxillofacial Plastic and Reconstructive Surgery
• /
• 제33권2호
• /
• pp.103-111
• /
• 2011

Purpose: Choukroun's platelet-rich-fibrin (PRF) is composed of platelets, white blood cells and fibrin matrix. It does not induce enough bone formation by itself but it can improve bone formation with calcium. Silk fibroin does not cause inflammatory reactions because it is bio-compatible and degradable. The purpose of this study was to exam the bone formation when a combination of Choukroun's PRF and silk fibroin was used. Methods: In this study, cell reactions to silk powder with differing molecular weights was first tested to select the appropriate silk powder. Then we applied these bone graft materials on defects of skull and in a peri-implant bony defect model in New Zealand rabbits. The results between the experimental and control s (non-grafted) group were analyzed. Results: The small sized silk fibroin powder showed increased cellular proliferation for bone-regeneration. There was no statistically significant difference between the experimental group and the control group at 6 weeks, but more new bone formation was observed in the combination graft group at 12 weeks (P<0.05). And in the dental implant model, the combination bone graft group showed much improved torque test results, which was statistically significant. Histomorphometric analysis showed more regenerated cortical bone and a higher mean bone to implant in the experimental group. Both were statistically significant. Conclusion: The combination graft of Choukroun's platelet-rich-fibrin (PRF) and silk fibroin powder can successfully restore the bony defects in a skull defected model and a peri-implant bony defects model.

• Radiation Oncology Journal
• /
• 제6권2호
• /
• pp.195-201
• /
• 1988

최근 폐암의 발생빈도는 높아지고 있으나, 아직까지 만족할 만한 치료 성적은 제시되시 많고 있으며, 현재로서는 가능한 한 초기에 발견하여 수술을 시행후 국소재발 위험군의 경우 방사선 치료를 시행하는 것이 최선의 방법으로 알려져있다. 이에 저자들은 1979년 3월부터 1986년 2월까지 서울대학교 병원에서 비소세포성 폐암 진단하에 근치적 절제수술 시행후 방사선 치료를 받은 60명의 환자를 대상으로 수술후 방사선 치료의 효과 및 예후인자에 대한 분석을 시행하여 다음과 같은 결과를 얻었다. 전체 환자 60명중 방사선 치료를 불완전하게 시행한 5명을 제외한 55명을 분석한 결과 전체 환자의 5년 생존율은 $39\%$였으며 무병생존율은 $29\%$였다. 환자의 예후를 결정하는 주요인자로서는 병기 및 국소 임파절 전이 여부였고, 1병기와 병리조직학적 분류 및 나이, 성별, 방사선 조사선량과 수술시 절제면의 종양 침범 여부는 예후에 큰 영향을 미치지 못하였다. 수술 시행후 방사선 치료를 받은 환자 군의 생존율은, 문헌상에 나타난 수술 단독 시행 환자군의 생존율과 비교해 볼 때 국소 임파절 전이가 있는 환자군에서 더 높은 결과를 보였으며, 임파절 전이가 없는 환자군에서는 큰 차이를 발견할 수 없었다. 국소 재발율도 임파절 전이가 있는 환자군에서는 수술 단독 시행 환자군보다 현저히 낮은 결과를 보여 수술후 방사선 치료가 임파절 전이가 있는 환자에게는 생존율의 증가 및 국소재발 억제의 효과를 나타냄을 관찰할 수 있었다.

• Radiation Oncology Journal
• /
• 제8권2호
• /
• pp.169-176
• /
• 1990

1980년 3월부터 1987년 8월까지 서울대학교병원 치료방사선과에서 망막아세포종으로 방사선 치료를 받았던 23예의 치료 성적을 보고한다. 20예의 편측성 종양에서, 13예는 안구적출술후 방사선치료를, 2예는 방사선치료만, 5예는 안구 적출후 동측 재발종양의 방사선치료를 받았다. 재발성 종양을 제외한 15예의 병기는 St. Jude Children's Research Hospital의 병기분류 기준에 의한 I 기(retinal)는 없고, II기(global) 5예, III기 (orbital) 8예, IV기 (cranial or metastatic) 2예였다. 양측성 종양 3예는 생후 1개월 이내에 증상이 나타났고, 진행된 종양측은 안구적출술을 시행했으며 조기 종양측은(3예 모두 I기)방사선 치료를 하였다. 시신경 절단부 또는 뇌척수액에서 종양 세포가 확인된 경우에는 항암화학치료를 병용하였다. 수술후 계획대로 방사선치료를 받은 12예의 5년 생존율은 $82.2\%$이며, 국소재발 또는 원격전이는 없었으나, 2환아(III기)의 진단시 무병상태였던 반대측 망막에서 종양이 속발하였다. 일차적 방사선 치료를 계획대로 받은 1예의 반대측 망막에서 종양이 속발하였다. 따라서 양측성 종양의 전반적 빈도는 $33\%$였다. 재발성종양 5예의 치료성적은 매우 불량하여 생존율은 $20\%$였다. 양측성 종양 3예중 2예가 무병상태로 생존하고 있다. 방사선 치료후의 변화로는 안와 연조직 위축이 관찰되었다. 방사선 치료성적은 조기 병기 또는 종양의 크기가 작은 경우에 양호하여 조기 치료가 중요하며 진단후 치료가 지연되지 않도록 함이 중요하다.

• 분석과학
• /
• 제26권1호
• /
• pp.42-50
• /
• 2013

이 논문은 센서 및 연료전지에 사용할 수 있는 $Pt-Ru@TiO_2-H$ 나노구조체촉매의 제조 및 전기화학적 촉매의 특성에 대한 것이다. 이 $Pt-Ru@TiO_2-H$ 나노구조체촉매는 주형제인 폴리스틸렌볼(PSB)을 제조하고, 이 주형제의 표면에 졸-겔 반응을 통해 $TiO_2$를 코팅한 후, $Pt^{4+}$와 $Ru^{3+}$의 환원에 의해 제조하였다. 제조된, $Pt-Ru@TiO_2-H$ 나노구조체촉매는 전자투과현미경(TEM), X-선 회절(XRD)와 원소분석에 의해 특성평가 하였고, $Pt-Ru@TiO_2-H$의 전기화학적 촉매특성은 에탄올, 메탄올, 도파민, 아스크로브 산, 프로말린과 글루코오즈의 산화-환원 능력에 의해 평가 하였다. 이 $Pt-Ru@TiO_2-H$ 나노구조체촉매는 바이오분자에 대해 전기화학적촉매 특성을 나타내어, 연료전지 전극 또는 비효소바이오센서에 사용 될 것으로 기대된다.

• The Korean Journal of Physiology and Pharmacology
• /
• 제21권3호
• /
• pp.309-316
• /
• 2017

Transient receptor potential vanilloid 3 (TRPV3) is a non-selective cation channel with modest permeability to calcium ions. It is involved in intracellular calcium signaling and is therefore important in processes such as thermal sensation, skin barrier formation, and wound healing. TRPV3 was initially proposed as a warm temperature sensor. It is activated by synthetic small-molecule chemicals and plant-derived natural compounds such as camphor and eugenol. Schisandra chinensis (Turcz.) Baill (SC) has diverse pharmacological properties including antiallergic, anti-inflammatory, and wound healing activities. It is extensively used as an oriental herbal medicine for the treatment of various diseases. In this study, we investigated whether SC fruit extracts and seed oil, as well as four compounds isolated from the fruit can activate the TRPV3 channel. By performing whole-cell patch clamp recording in HEK293T cells overexpressing TRPV3, we found that the methanolic extract of SC fruit has an agonistic effect on the TRPV3 channel. Furthermore, electrophysiological analysis revealed that ${\gamma}$-schisandrin, one of the isolated compounds, activated TRPV3 at a concentration of $30{\mu}M$. In addition, ${\gamma}$-schisandrin (${\sim}100{\mu}M$) increased cytoplasmic $Ca^{2+}$ concentrations by approximately 20% in response to TRPV3 activation. This is the first report to indicate that SC extract and ${\gamma}$-schisandrin can modulate the TRPV3 channel. This report also suggests a mechanism by which ${\gamma}$-schisandrin acts as a therapeutic agent against TRPV3-related diseases.

• Asian Pacific Journal of Cancer Prevention
• /
• 제16권7호
• /
• pp.2915-2921
• /
• 2015

Background: Some recent clinical trials have been conducted to evaluate a combination of EGFR- TKI with chemotherapy for advanced NSCLC patients as second-line therapy, but the results on the efficacy of such trials are inconsistent. The aim of this meta-analysis was to evaluate the efficacy and safety of combination of EGFR-TKI and chemotherapy for patients with advanced NSCLC who failed first-line treatment. Materials and Methods: We searched relative trials from PubMed, EMBASE, ASCO Abstracts, ESMO Abstracts, Cochrane Library and Clinical Trials.gov. Outcomes analyzed were overall response rate (ORR), progression- free survival (PFS), overall survival (OS) and major toxicity. Results: Seven trails eventually were included in this meta-analysis, covering 1,168 patients. The results showed that the combined regimen arm had a significant higher ORR (RR 1.76 [1.16, 2.66], p=0.007) and longer PFS (HR 0.75 [0.66-0.85], p<0.00001), but failed to show effects on OS (HR 0.88 [0.68-1.15], p=0.36). In terms of subgroup results, continuation of EGFR-TKI in addition to chemotherapy after first-line EGFR-TKI resistance confered no improvement in ORR (RR 0.95 [0.68, 1.33], p=0.75) and PFS (HR 0.89[0.69, 1.15], p=0.38), and OS was even shorter (HR1.52 [1.05-2.21], p=0.03). However, combination therapy with EGFR-TKI and chemotherapy after failure of first-line chemotherapy significantly improved the ORR (RR 2.06 [1.42, 2.99], p=0.0002), PFS (HR 0.71 [0.61, 0.82], p<0.00001) and OS (HR 0.74 [0.62-0.88], p=0.0008), clinical benefit being restricted to combining EGFR-TKI with pemetrexed, but not docetaxel. Grade 3-4 toxicity was found at significantly higher incidence in the combined regimen arm. Conclusions: Continuation of EGFR-TKI in addition to chemotherapy after first-line EGFR-TKI resistance should be avoided. Combination therapy of EGFR-TKI and pemetrexed for advanced NSCLC should be further investigated for prognostic and predictive factors to find the group with the highest benefit of the combination strategy.

• Tuberculosis and Respiratory Diseases
• /
• 제75권2호
• /
• pp.59-66
• /
• 2013

Background: This study was conducted in order to elucidate the effects of docetaxel on the growth of peroxiredoxin 1 (Prx1) knockdown A549 xenograft tumors and further tested the role of Prx1 as a predictor for how a patient would respond to docetaxel treatment. Methods: Effects of docetaxel on the growth of scrambled- and shPrx1-infected A549 xenograft tumors in nude mice were measured. Moreover, immunohistochemical expression of Prx1 was evaluated in paraffin-embedded tissues from 24 non-small cell lung cancer patients who had received docetaxel-cisplatin regimens as a first-line treatment. Results: Docetaxel treatment in Prx1 knockdown xenograft tumor resulted in reduced tumors growth compared with other groups. Prx1 knockdown increased the production of cleaved caspases-8 and -9 in the control itself compared to scramble tumors. Moreover, docetaxel treatment in Prx1 knockdown tissue led to an increased protein band. Phosphorylated Akt was found in Prx1 scramble tissues. Phosphorylated FOXO1 was detected in the docetaxel treatment group. On the other hand, Prx1 knockdown completely suppressed the Akt-FOXO1 axis. The median progression-free survival (PFS) of patients with low Prx1 expression was 7 months (95% confidence interval [CI], 6.0-7.7), whereas the median progression-free survival of patients with high Prx1 expression was 4 months (95% CI, 4.0-5.0). However, high Prx1 expression was not associated with decreased PFS (p=0.114). Conclusion: Our findings suggest that elevated Prx1 provides resistance to docetaxel treatment through suppression of FOXO1-induced apoptosis in A549 xenograft tumors, but may not be related with the predictive significance for response to docetaxel treatment.

• Asian Pacific Journal of Cancer Prevention
• /
• 제13권12호
• /
• pp.6139-6144
• /
• 2012

Aims: Mammalian target of rapamycin (mTOR) is master regulator of the PI3K/Akt/mTOR pathway and plays an important role in NSCLCs. Here we characterized mRNA and protein expression levels of mTOR and its functional associated molecules including PTEN, IGF-1R and 4EBP1 in surgically resected NSCLCs. Methods: Fifty-four patients with NSCLCs who underwent pulmonary resection were included in current study. mRNA levels of mTOR, PTEN, IGF-1R, and 4EBP1 were evaluated by RT-PCR and protein expression of mTOR, PTEN, and IGF-1R by immunohistochemistry (IHC). Association of expression of the relevant molecules with clinical characteristics, as well as correlations between mTOR and PTEN, 4EBP1 and IGF-1R were also assessed. Results: The results of RT-PCR showed that in NSCLCs, the expression level of mTOR increased, while PTEN, 4EBP1 and IGF-1R decreased. Statistical analysis indicated high IGF-1R expression was correlated with advanced clinical stage (stage III) and PTEN expression was reversely associated with tumor size (P=0.16). The results of IHC showed mTOR positive staining in 51.8% of cases, while IGF-1R positive staining was found in 83.3% and loss of PTEN in 46.3%. Protein expression of mTOR was correlated with its regulators, PTEN and IGF-1R, to some extent. Conclusions: Abnormal activation of mTOR signaling, high expression of IGF-1R, and loss of PTEN were observed in resected NSCLC specimens. The poor expression agreement of mTOR with its regulators, PTEN, and IGF-1R, implied that combination strategy of mTOR inhibitors with other targets hold significant potential for NSCLC treatment.